Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04441138 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
A Phase 2 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04441138 is a Phase 2 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04441138, a Phase 2 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Elderly (age 70 years or older) or \>18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalumab (MEDI4736).
Interventions
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04441138
The ClinicalTrials.gov registry entry for NCT04441138 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Durvalumab is the first listed.
NCT04441138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04441138 about?
NCT04441138 is a clinical study titled "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC". Elderly (age 70 years or older) or \>18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalu...
What is the current status of trial NCT04441138?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-02-25. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04441138?
The interventions under investigation include: Durvalumab (DRUG).
Who is sponsoring clinical trial NCT04441138?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.